According to Newron Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -5.35. At the end of 2023 the company had a P/S ratio of 10.5.
Year | P/S ratio | Change |
---|---|---|
2023 | 10.5 | 129.1% |
2022 | 4.58 | -5.53% |
2021 | 4.85 | -27.95% |
2020 | 6.73 | -54.65% |
2019 | 14.8 | -32.87% |
2018 | 22.1 | 67.79% |
2017 | 13.2 | -76.3% |
2016 | 55.6 | -60.74% |
2015 | 142 | -22.44% |
2014 | 183 | 305.31% |
2013 | 45.0 | 430.01% |
2012 | 8.50 | 177.83% |
2011 | 3.06 | -94.23% |
2010 | 53.0 | 62.88% |
2009 | 32.6 | 123.09% |
2008 | 14.6 | -66.81% |
2007 | 44.0 | -72.9% |
2006 | 162 |